diabetes

Showing 15 posts of 392 posts found.

Sanofi diabetes drug fails to show cardio disease benefit

March 19, 2015
Research and Development, Sales and Marketing ACS, Lixisenatide, Lyxumia, Sanofi, cardio, diabetes

A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …

Sanofi sees FDA approval for diabetes drug

February 26, 2015
Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4

US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …

Merck invests $450m in NGM Biopharma

February 23, 2015
Sales and Marketing Merck, NGM Biopharma, NP201, diabetes, nonalcoholic steatohepatitis, obesity

Merck is to collaborate on drug development with biotech firm NGM Pharmaceuticals in a $450 million deal. The collaboration will …

Sanofi sales lifted by diabetes and rare diseases

February 6, 2015
Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4

Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …

AstraZeneca looks for revenue boost via Actavis buy

February 6, 2015
Sales and Marketing Actavis, AstraZeneca, Brilinta, Forxiga, diabetes, fourth quarter, q4

AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …

Sanofi’s inhalable insulin goes on sale in US

February 3, 2015
Sales and Marketing Afrezza, FDA, Mannkind, Sanofi, US, apidra, diabetes, insulin, type 1, type 2

Sanofi has launched its inhalable insulin Afrezza in the US to control blood sugar in people with type 1 and …

Needle-free device shows potential in diabetes

January 23, 2015
Medical Communications, Sales and Marketing Cygnus, University of California, diabetes, tattoo

A ‘tattoo-like’ ultra-thin sensor that sits on the skin has been developed that could help patients monitor their blood glucose …

FDA approves novel obesity device

January 16, 2015
Medical Communications, Sales and Marketing EnteroMedics, FDA, Novo, VBLOC, diabetes, obesity, type 2

The US Food and Drug Administration has shown the green light to US firm EnteroMedics’ new obesity device VBLOC that …

Sanofi and Boehringer partner on biologics manufacturing

January 15, 2015
Manufacturing and Production, Sales and Marketing Boehringer, Sanofi, antibodies, biologics, cardiovascular, diabetes, mabs, manufacturing, monoclonal, oncology

Boehringer Ingelheim will help Sanofi extend its manufacturing capabilities for biologics in a new alliance, the companies have announced. Boehringer’s …

Novo Nordisk obesity drug gets FDA nod

December 24, 2014
Sales and Marketing FDA, Novo Nordisk, Victoza, diabetes, liraglutide, saxenda

The US Food and Drug Administration has shown Novo Nordisk’s obesity drug Saxenda the green light to aid chronic weight …

NICE changes insulin advice in diabetes guidelines

December 12, 2014
Sales and Marketing NHS, NICE, diabetes, health survey, insulin, type 1, type 2

NICE has changed its recommendations on type 1 diabetes in adults and children, and type 2 diabetes in children, to …

Roche buys Ariosa Diagnostics

December 2, 2014
Research and Development, Sales and Marketing IPF, IQuum, InterMune, Roche, ariosa, cfdna, diabetes, genia, seragon

Roche has purchased the privately-held US company Ariosa Diagnostics for an undisclosed fee as it looks to expand further into …

AstraZeneca diabetes drug approved for use in Scotland

November 11, 2014
Sales and Marketing Afinitor, AstraZeneca, Eylea, Onglyza, Perjeta, SMC, diabetes, type 2

The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …

Novo Nordisk to open $130 million diabetes labs

November 3, 2014
Manufacturing and Production, Sales and Marketing Denmark, Måløv, Novo Nordisk, Tresiba, Victoza, diabetes

Novo Nordisk has invested $130 million in new diabetes laboratories as the company looks to focus more strongly on the …

Takeda and Lilly get Actos trial reprieve

October 29, 2014
Sales and Marketing Actos, Takeda, bladder cancer, diabetes, lilly

A judge has dramatically reduced the $9 billion damages bill Takeda and Lilly were set to pay over safety allegations …

The Gateway to Local Adoption Series

Latest content